Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Captopril + losartan is a combination of two antihypertensive agents, each targeting the renin-angiotensin system through distinct mechanisms. Captopril is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced blood pressure. Losartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the type 1 (AT1) receptor on vascular smooth muscle and adrenal gland tissues, also resulting in vasodilation and decreased blood pressure. The combination may provide additive effects on lowering blood pressure by inhibiting both production and action of angiotensin II[4][6]. Both drugs are primarily indicated for hypertension; they may also be used in other cardiovascular conditions such as heart failure or nephropathy depending on clinical context. However, concurrent use increases risk for adverse effects such as hypotension and renal impairment[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on captopril + losartan.